Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity (MoMo-NfL)

Centre Hospitalier Universitaire de Nīmes

Status

Not yet enrolling

Conditions

Multiple Sclerosis (MS) - Relapsing-remitting

Treatments

Other: Monthly pNfL monitoring

Study type

Interventional

Funder types

Other

Identifiers

NCT07292480

FINEX/2025/ET-01

Details and patient eligibility

About

Reference MRI scan is recommended 6 months after treatment onset in patients with multiple sclerosis (MS), and follow-up scans at 12 months later to monitor subclinical activity. When monitoring treatment response in patients treated with disease modifying treatments (DMTs), the measurement of new or enlarging T2/FLAIR hyperintense lesions (NELs) is the preferred MRI method supplemented by contrast-enhancing lesions (CELs) for monitoring treatment response. However, some studies have suggested the deposition of gadolinium-based contrast agents in the basal ganglia and dentate nucleus of patients who underwent serial MRI acquisitions. Although significant clinical consequences of these deposits have not been demonstrated, further studies are required to better understand the potential long-term biological and clinical effects of gadolinium administration. To circumvent this potential risk, several recommendations suggested avoiding unnecessary use of gadolinium for follow-up scans. New sequences are also developed to replace gadolinium injection for the detection of active lesions. Moreover, MRI remains costly and time-consuming. In addition, systematic yearly MRI monitoring is not adapted to detect silent active lesions. This can delay identification of treatment failure and increase the risk of relapses and disability worsening, especially in the context of escalation therapy.

Therefore, biological markers could allow more frequent analysis of disease activity and detect treatment failure earlier than classical clinical and MRI monitoring. Their use would greatly help clinicians to switch for high efficacy treatments (HET) and avoid potential relapses.

Measurement of a structural axonal protein, neurofilament, in serum or plasma has shown promise as a marker of neuroaxonal injury and a measure of treatment response. In MS, cerebrospinal fluid (CSF) neurofilament-light chain (NfL) is also increased and is positively associated with MRI lesion load and disability scores and is a marker of treatment response.

WThe study authors hypothesize that monthly plasma neurofilament-light chain (pNfL) monitoring can sensitively highlight subclinical (radiological disease activity) RDA by performing early MRI scans to confirm EDA and lead to timely treatment escalation.

The main objective of this study is to compare the time to EDA in both arms (monthly pNfL monitoring vs. standard care with regular MRI scans), in patients with EDA.

Enrollment

84 estimated patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient with RRMS according to 2017 McDonald's criteria.
Less than 5 years from disease onset.
Active RRMS (EDA) observed during the last 24 months: relapse and/or NELs and/or CELs as compared to a previous MRI performed within 24 months (± 3 months).
MET (IFN, GA, TE, fumarates) for less than 24 months.
Standard MRI follow-up scan performed less than 30 days before inclusion.
Clinically stable disease for at least 30 days.
Patients included in observational studies and cohorts (OFSEP, PROMISE …) will be eligible for inclusion in MoMo-NfL.
For women with reproductive potential: negative pregnancy test at the time of inclusion and use of an effective method to avoid pregnancy for the duration of the trial.
Patients able to adhere to the study visit schedule.
Patient must have signed and given the consent.
Patient affiliated or beneficiary of a health insurance plan.

Exclusion criteria

Pregnant or breastfeeding woman.
Patient unable to perform brain and/or spinal cord MRI scans.
Patient not willing to perform monthly blood punctures.
Patient treated with HET (S1P agonists, natalizumab, ocrelizumab, ofatumumab, rituximab, alemtuzumab, cladribine, mitoxantrone).
Patient with a relapse within 6 months before inclusion.
Patient with CELs within 3 months before inclusion.
Patient with progressive MS.
Patient unable to sign the consent.
It is impossible to correctly inform the patient.
Patient being involved or having been involved in an interventional research (RIPH type 1 or drug research or clinical investigation of medical device) 3 months before the inclusion visit.
Patient under judicial protection, or is an adult under guardianship.
Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control for the duration of the trial.